JM Bartlett

Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.

SE Jones, C. Seynaeve, Annette Hasenburg et al. · Cancer Research · 2009 · 63 citations

Medicine, Endocrinology, Oncology +17

A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy.

Angelo Di Leo, J Isola, Fanny Piette et al. · Cancer Research · 2009 · 57 citations

Medicine, Cancer Biology, Oncology +16

Growth control by epidermal growth factor and transforming growth factor-α in human lung squamous carcinoma cells

G. J. Rabiasz, SP Langdon, JM Bartlett et al. · British Journal of Cancer · 1992 · 28 citations · Full text

Medicine, Cell Biology, Oncology +15

Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines?.

JM Bartlett, Christine Desmedt, Alison F. Munro et al. · Cancer Research · 2009 · 12 citations

Life Sciences, Genetics, Oncology +17